| Hans-Günter Meyer-Thompson | HIV
US FDA approves Gilead's twice-yearly injection for HIV prevention
US FDA approves Gilead's twice-yearly injection for HIV prevention
June 18 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences (GILD.O)vlenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.vGilead said the drug will be sold under the brand name Yeztugo. (Reuters, USA, 18.06.2025)
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-gileads-twice-yearly-injection-hiv-prevention-2025-06-18/